Your shopping cart is currently empty

Riviciclib is a potent inhibitor of cyclin-dependent kinase (CDK)(CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively),with antitumor activity on cisplatin-resistant cells.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,820 | 1-2 weeks | 1-2 weeks | |
| 50 mg | $2,380 | 1-2 weeks | 1-2 weeks | |
| 100 mg | $3,100 | 1-2 weeks | 1-2 weeks |
| Description | Riviciclib is a potent inhibitor of cyclin-dependent kinase (CDK)(CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively),with antitumor activity on cisplatin-resistant cells. |
| Targets&IC50 | CDK6-CyclinD1:0.396 μM, CDK2-CyclinE:2.540 μM, CDK2-CyclinA:0.224 μM, CDK1-CyclinB:0.079 μM, CDK4-CyclinD1:0.063 μM, CDK9-CyclinT1:0.020 μM, CDK9-CyclinH:2.900 μM |
| In vitro | Riviciclib (3-24 hours; 1.5 μM) reduces cyclin D1, Cdk4, and Rb levels in H-460 cells. Rb (retinoblastoma) phosphorylation at Ser780 decrease at 3 h. Riviciclib shows activity in human cancer cell lines, such as colon carcinoma, osteosarcomal, cervical carcinoma, and bladder carcinoma cells[2].Riviciclib shows no detectable cells in G1 and G2 in promyelocytic leukemia cells and arrest of cells in G1 in synchronized human non-small cell lung carcinoma (H-460) and human normal lung fibroblast (WI-38) cells[3]. |
| In vivo | Riviciclib in human xenograft mode with severe combined immunodeficient mice shows significant inhibition in the growth of human colon carcinoma HCT-116 xenograft[3]. |
| Synonyms | P276-00 (free base) |
| Molecular Weight | 401.84 |
| Formula | C21H20ClNO5 |
| Cas No. | 920113-02-6 |
| Smiles | OC=1C(=C2C(C(=O)C=C(O2)C3=C(Cl)C=CC=C3)=C(O)C1)[C@H]4[C@H](CO)N(C)CC4 |
| Relative Density. | 1.429 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.